Radiolabeled tracers targeting the prostate-specific membrane antigen (PSMA) have become\nimportant radiopharmaceuticals for the PET-imaging of prostate cancer. In this connection, we\nrecently developed the fluorine-18-labelled PSMA-ligand [18F]PSMA-1007 as the next generation\nradiofluorinated Glu-ureido PSMA inhibitor after [18F]DCFPyL and [18F]DCFBC. Since radiosynthesis\nso far has been suffering from rather poor yields, novel procedures for the automated radiosyntheses\nof [18F]PSMA-1007 have been developed. We herein report on both the two-step and the novel\none-step procedures, which have been performed on different commonly-used radiosynthesisers.\nUsing the novel one-step procedure, the [18F]PSMA-1007 was produced in good radiochemical yields\nranging from 25 to 80% and synthesis times of less than 55 min. Furthermore, upscaling to product\nactivities up to 50 GBq per batch was successfully conducted. All batches passed quality control\naccording to European Pharmacopoeia standards. Therefore, we were able to disclose a new, simple\nand, at the same time, high yielding production pathway for the next generation PSMA radioligand\n[18F]PSMA-1007. Actually, it turned out that the radiosynthesis is as easily realised as the well-known\n[18F]FDG synthesis and, thus, transferable to all currently-available radiosynthesisers. Using the new\nprocedures, the clinical daily routine can be sustainably supported in-house even in larger hospitals\nby a single production batch.
Loading....